We are committed to expanding our Generics division by targeting complex solid oral and alternative dosage form Abbreviated New Drug Applications (ANDAs) with high-value, difficult to develop, first-to-file or first-to-market product opportunities. Our development capabilities are industry-leading and span all dosage forms, including complex oral solids, injectables, ophthalmics, liquids, topicals and transdermals.
The Amneal Generics pipeline is currently one of the industry’s largest, including more than 280 products filed with the FDA or in development*. This pipeline includes products across a broad range of therapeutic areas including cardiovascular, central nervous system/pain, oncology, inflammation, anti-infective, dermatology, endocrinology, diabetes, rhinology, urology, and hematology, among others.
We are also excited about our work to bring patients more affordable biologic therapy options through our growing biosimilars program, which today includes one filed product, one near-term filing opportunity and one product under development.
*As of May 2018